Topic: postapproval marketing
With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.
With psychosis med Nuplazid facing a DOJ probe and schizophrenia flop, Acadia hopes a new round of TV ads will help court more patients.
Amarin is doubling down on its heart drug Vascepa, aiming to raise $400 million-plus in a stock offering. But investors aren't thrilled with the idea.
Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a good idea.
Novo Nordisk has seen its position in the Chinese diabetes market whittled away in the last couple of years, but it says new products will keep it on top.
Dr. Reddy's will sell three of Amgen's already-approved drugs in India, extending an earlier deal involving three late-stage pipeline candidates.